Literature DB >> 28162099

Cost-effectiveness of active case-finding of household contacts of pulmonary tuberculosis patients in a low HIV, tuberculosis-endemic urban area of Lima, Peru.

L Shah1, M Rojas2, O Mori2, C Zamudio3, J S Kaufman1, L Otero3, E Gotuzzo3, C Seas3, T F Brewer4.   

Abstract

We compared the cost-effectiveness (CE) of an active case-finding (ACF) programme for household contacts of tuberculosis (TB) cases enrolled in first-line treatment to routine passive case-finding (PCF) within an established national TB programme in Peru. Decision analysis was used to model detection of TB in household contacts through: (1) self-report of symptomatic cases for evaluation (PCF), (2) a provider-initiated ACF programme, (3) addition of an Xpert MTB/RIF diagnostic test for a single sputum sample from household contacts, and (4) all strategies combined. CE was calculated as the incremental cost-effectiveness ratio (ICER) in terms of US dollars per disability-adjusted life years (DALYs) averted. Compared to PCF alone, ACF for household contacts resulted in an ICER of $2155 per DALY averted. The addition of the Xpert MTB/RIF diagnostic test resulted in an ICER of $3275 per DALY averted within a PCF programme and $3399 per DALY averted when an ACF programme was included. Provider-initiated ACF of household contacts in an urban setting of Lima, Peru can be highly cost-effective, even including costs to seek out contacts and perform an Xpert/MTB RIF test. ACF including Xpert MTB/RIF was not cost-effective if TB cases detected had high rates of default from treatment or poor outcomes.

Entities:  

Keywords:  Case-finding; community epidemics; cost-effectiveness; public health; tuberculosis (TB)

Mesh:

Year:  2017        PMID: 28162099      PMCID: PMC9507832          DOI: 10.1017/S0950268816003186

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   4.434


  24 in total

Review 1.  Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review.

Authors:  Karen R Steingart; Megan Henry; Vivienne Ng; Philip C Hopewell; Andrew Ramsay; Jane Cunningham; Richard Urbanczik; Mark Perkins; Mohamed Abdel Aziz; Madhukar Pai
Journal:  Lancet Infect Dis       Date:  2006-09       Impact factor: 25.071

Review 2.  Xpert® MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults.

Authors:  Karen R Steingart; Ian Schiller; David J Horne; Madhukar Pai; Catharina C Boehme; Nandini Dendukuri
Journal:  Cochrane Database Syst Rev       Date:  2014-01-21

3.  Prevalence of and risk factors for resistance to second-line drugs in people with multidrug-resistant tuberculosis in eight countries: a prospective cohort study.

Authors:  Tracy Dalton; Peter Cegielski; Somsak Akksilp; Luis Asencios; Janice Campos Caoili; Sang-Nae Cho; Vladislav V Erokhin; Julia Ershova; Ma Tarcela Gler; Boris Y Kazennyy; Hee Jin Kim; Kai Kliiman; Ekaterina Kurbatova; Charlotte Kvasnovsky; Vaira Leimane; Martie van der Walt; Laura E Via; Grigory V Volchenkov; Martin A Yagui; Hyungseok Kang; Rattanawadee Akksilp; Wanlaya Sitti; Wanpen Wattanaamornkiet; Sofia N Andreevskaya; Larisa N Chernousova; Olga V Demikhova; Elena E Larionova; Tatyana G Smirnova; Irina A Vasilieva; Alena V Vorobyeva; Clifton E Barry; Ying Cai; Isdore C Shamputa; Jaime Bayona; Carmen Contreras; Cesar Bonilla; Oswaldo Jave; Jeannette Brand; Joey Lancaster; Ronel Odendaal; Michael P Chen; Lois Diem; Beverly Metchock; Kathrine Tan; Allison Taylor; Melanie Wolfgang; Eunjin Cho; Seok Yong Eum; Hyun Kyung Kwak; Jiim Lee; Jongseok Lee; Seonyeong Min; Irina Degtyareva; Evgenia S Nemtsova; Tatiana Khorosheva; Elena V Kyryanova; Grace Egos; Ma Therese C Perez; Thelma Tupasi; Soo Hee Hwang; Chang-ki Kim; Su Young Kim; Hee Jeong Lee; Liga Kuksa; Inga Norvaisha; Girts Skenders; Ingrida Sture; Tiina Kummik; Tatiana Kuznetsova; Tatiana Somova; Klavdia Levina; Gustavo Pariona; Gloria Yale; Carmen Suarez; Eddy Valencia; Piret Viiklepp
Journal:  Lancet       Date:  2012-08-30       Impact factor: 79.321

4.  Community DOT for tuberculosis in a Brazilian favela: comparison with a clinic model.

Authors:  S C Cavalcante; E C C Soares; A G F Pacheco; R E Chaisson; B Durovni
Journal:  Int J Tuberc Lung Dis       Date:  2007-05       Impact factor: 2.373

5.  Predictors of poor outcomes among patients treated for multidrug-resistant tuberculosis at DOTS-plus projects.

Authors:  Ekaterina V Kurbatova; Allison Taylor; Victoria M Gammino; Jaime Bayona; Mercedes Becerra; Manfred Danilovitz; Dennis Falzon; Irina Gelmanova; Salmaan Keshavjee; Vaira Leimane; Carole D Mitnick; Ma Imelda Quelapio; Vija Riekstina; Piret Viiklepp; Matteo Zignol; J Peter Cegielski
Journal:  Tuberculosis (Edinb)       Date:  2012-07-10       Impact factor: 3.131

6.  Rapid molecular detection of tuberculosis and rifampin resistance.

Authors:  Catharina C Boehme; Pamela Nabeta; Doris Hillemann; Mark P Nicol; Shubhada Shenai; Fiorella Krapp; Jenny Allen; Rasim Tahirli; Robert Blakemore; Roxana Rustomjee; Ana Milovic; Martin Jones; Sean M O'Brien; David H Persing; Sabine Ruesch-Gerdes; Eduardo Gotuzzo; Camilla Rodrigues; David Alland; Mark D Perkins
Journal:  N Engl J Med       Date:  2010-09-01       Impact factor: 91.245

Review 7.  DOTS expansion: will we reach the 2005 targets?

Authors:  L J Véron; L J Blanc; M Suchi; M C Raviglione
Journal:  Int J Tuberc Lung Dis       Date:  2004-01       Impact factor: 2.373

8.  Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru.

Authors:  Pedro G Suárez; Katherine Floyd; Jaime Portocarrero; Edith Alarcón; Elisabetta Rapiti; Gilbert Ramos; Cesar Bonilla; Ivan Sabogal; Isabel Aranda; Christopher Dye; Mario Raviglione; Marcos A Espinal
Journal:  Lancet       Date:  2002-06-08       Impact factor: 79.321

9.  Cost-effectiveness of a tuberculosis active case finding program targeting household and neighborhood contacts in Cambodia.

Authors:  Rajendra P Yadav; Nobuyuki Nishikiori; Peou Satha; Mao T Eang; Yoel Lubell
Journal:  Am J Trop Med Hyg       Date:  2014-03-10       Impact factor: 2.345

10.  How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India.

Authors:  Andrew S Azman; Jonathan E Golub; David W Dowdy
Journal:  BMC Med       Date:  2014-10-30       Impact factor: 8.775

View more
  5 in total

1.  Costs and operation management of community outreach program for tuberculosis in tribal populations in India.

Authors:  H Sohn; A Vyas; L Puri; S Gupta; Z Z Qin; A Codlin; J Creswell
Journal:  Public Health Action       Date:  2019-06-21

2.  Cost-Utility Analysis of Molecular Testing for Tuberculosis Diagnosis in Suspected Pulmonary Tuberculosis in Thailand.

Authors:  Natthakan Chitpim; Jiraphun Jittikoon; Wanvisa Udomsinprasert; Surakameth Mahasirimongkol; Usa Chaikledkaew
Journal:  Clinicoecon Outcomes Res       Date:  2022-02-02

3.  Tuberculosis screening costs and cost-effectiveness in high-risk groups: a systematic review.

Authors:  H Alsdurf; B Empringham; C Miller; A Zwerling
Journal:  BMC Infect Dis       Date:  2021-09-08       Impact factor: 3.090

4.  Cost-effectiveness of household contact investigation for detection of tuberculosis in Pakistan.

Authors:  Hamidah Hussain; Amyn Malik; Junaid F Ahmed; Sara Siddiqui; Farhana Amanullah; Jacob Creswell; Thorkild Tylleskär; Bjarne Robberstad
Journal:  BMJ Open       Date:  2021-10-22       Impact factor: 3.006

5.  HIV prevalence and TB in migrant miners communities of origin in Gaza Province, Mozambique: The need for increasing awareness and knowledge.

Authors:  Cynthia Semá Baltazar; Yara Voss DeLima; Helena Ricardo; Carlos Botão; Denise Chitsondzo Langa; Paulino da Costa; Diosdélio Malamule; Ângelo Augusto; Sofia Viegas; Nkechi Obisie-Nmehielle; Laura Tomm-Bonde; Francis Bwambale Mulekya
Journal:  PLoS One       Date:  2020-04-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.